Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, a selective immunoproteasome inhibitor is in a Phase 2 clinical trial in lupus nephritis, also holding the potential to address multiple chronic immune-mediated diseases.